Management Team

Mr. Iwicki has more than 30 years of biopharmaceutical industry experience. He was previously Chief Executive Officer of KALA BIO. Mr. Iwicki currently serves as the Chair of board of directors of KALA BIO and also serves on the boards of directors of Nimbus, Akero Therapeutics, Third Harmonic Bio, Q32 Bio and Merus. He previously served as President and Chief Executive Officer of Civitas Therapeutics and Sunovion Pharmaceuticals Inc. He was also President and Chief Executive Officer of Blend Therapeutics, and President and Chief Operating Officer at Sepracor. Earlier in his career, he was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation and held management positions at Astra Merck Inc. and Merck & Co. He previously served on the board of Aimmune Therapeutics. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.

Mr. McIntyre, 54, has over two decades of executive experience in the life sciences sector, having held various C-suite level roles at public and private biotech and medical device entities. He previously served as chief financial officer of Anthos Therapeutics, Inc. from October 2021 to October 2024. Before that, Mr. McIntyre served as chief financial officer of Tessa Therapeutics, Inc. from October 2020 to October 2021 and as chief financial officer and chief operating officer of  HeartWare® International, Inc. Mr. McIntyre also held positions at AVITA Medical, Inc. and Braeburn, Inc. Mr. McIntyre’s experience additionally includes nearly ten years as a Partner at Apple Tree Partners, a life science venture capital and growth equity fund. Prior to entering life sciences, he practiced as a senior attorney at Baker & McKenzie and KPMG. Mr. McIntyre currently serves on the board of directors of Starpharma Holdings Limited and Redflex Holdings Ltd. Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, Australia, a Bachelor of Laws from the University of Technology, Sydney, Australia and a Master of Business Administration (MBA) from Duke University Fuqua School of Business (Fuqua Scholar) from Durham, North Carolina, USA. Mr. McIntyre is a Certified Practicing Accountant and is also admitted as a legal practitioner of the Supreme Court of New South Wales and of the High Court of Australia.

Dr. Chris Cabell is the President, Head of Research and Development, and Chief Medical Officer of Inhibikase Therapeutics. Prior to this, Dr. Cabell served as Chief Executive Officer of CorHepta Pharmaceuticals which was acquired by Inhibikase. Previously, he served as Head of Clinical Development and CMO at Zura Bio and Emergent BioSolutions. Prior to that he spent 3 years at Arena Pharmaceuticals with increasing responsibilities including Chief Medical Officer and Head of Research and Development and he started his career as an Associate Professor of Medicine in the Division of Cardiology, Department of Medicine, Duke University School of Medicine. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is a honors graduate of Pennsylvania State University and Duke University, earning both his Medical Degree and a Masters in Health Sciences from the latter.

Dr. Adams joins Inhibikase from CorHepta where he was co-founder and Chief Scientific Officer. Previously he was Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals, and the Head of Research at Arena Pharmaceuticals. Dr. Adams earned his PhD in Physiological Science at UCLA and his B.S. Biological Sciences from U.C. Santa Barbara.

Jeff brings a wealth of experience leading human resources & corporate administration in fast-growing life sciences organizations. He has a solid mix of private and public company experience, as well as, a deep talent acquisition, talent management, & organizational development background. Prior to 2008, Jeff successfully managed his own HR consulting practice for over 15 years.

Chad Orevillo has over 30 years of experience in pharmaceutical clinical development and operations and program management. Prior to joining Inhibikase, he was co-founder and Executive Vice President and Head of Operations for Longboard Pharmaceuticals and before that served as Vice President and Head of Clinical Operations at Arena Pharmaceuticals. Earlier in his career, Chad held management roles at Merck, Pharmacia, Pfizer, Novartis, Pearl Therapeutics and Astrazeneca. Chad holds a Master in Public Health from Tulane University, a Bachelor of Science from William Paterson University and is a US Marine Corps veteran.